HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma
- 24 April 2023
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (2) , 262-270
Abstract
Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been implicated as a promising potential in cancer treatment. Therefore, the present study aimed to investigate the repurposing of raltegravir as an anticancer agent and its mechanism of action in multiple myeloma (MM). Human MM cell lines (RPMI‐8226, NCI H929, and U266) and normal peripheral blood mononuclear cells (PBMCs) were cultured with different concentrations of raltegravir for 48 and 72 h. Cell viability and apoptosis were then measured by MTT and Annexin V/PI assays, respectively. Protein levels of cleaved PARP, Bcl‐2, Beclin‐1, and phosphorylation of histone H2AX were detected by Western blotting. In addition, the mRNA levels of V(D)J recombination and DNA repair genes were analyzed using qPCR. Raltegravir treatment for 72 h significantly decreased cell viability, increased apoptosis, and DNA damage in MM cells while having minimum toxicity on cell viability of normal PBMCs approximately from 200 nM (0.2 μM; p < .01 for U66 and p < .0001 for NCI H929 and RPMI 8226 cells). Furthermore, raltegravir treatment altered the mRNA levels of V(D)J recombination and DNA repair genes. We report for the first time that treatment with raltegravir is associated with decreased cell viability, apoptosis induction, DNA damage accumulation, and alteration of mRNA expression of genes involved in V(D)J recombination and DNA repair in MM cell lines, all of which show its potential for anti‐myeloma effects. Hence, raltegravir may significantly impact the treatment of MM, and further studies are required to confirm its efficacy and mechanism of action in more detail in patient‐derived myeloma cells and in‐vivo models.Keywords
Funding Information
- Ankara Universitesi
This publication has 16 references indexed in Scilit:
- The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In VivoCancers, 2021
- HIV‑1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG‑mediated recombination (Review)Molecular Medicine Reports, 2019
- RAG1 high expression associated with IKZF1 dysfunction in adult B-cell acute lymphoblastic leukemiaJournal of Cancer, 2019
- Maneuvers on PCNA Rings during DNA Replication and RepairGenes, 2018
- HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombinationCell Death & Disease, 2017
- Structural Basis of Mos1 Transposase Inhibition by the Anti-retroviral Drug RaltegravirACS Chemical Biology, 2014
- Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer CellsPLOS ONE, 2009
- Raltegravir: first in class HIV integrase inhibitorTherapeutics and Clinical Risk Management, 2008
- Effect of HIV integrase inhibitors on the RAG1/2 recombinaseProceedings of the National Academy of Sciences, 2001
- Distinct Roles of RAG1 and RAG2 in Binding the V(D)J Recombination Signal SequencesMolecular and Cellular Biology, 1998